Functional Movement DisorderNCT07302308
Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.
An observational study of Functional Movement Disorder, run by Western University, Canada at 1 site in Canada.
Trial summary
Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Functional Movement Disorder
- How many people
- 30 participants
- Where
- 1 siteCanada
- Study dates
- 31 Jan 2026to 31 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: movement disorder clinic
Who may be able to join
- Age >18 years.
- Able to read and understand English
Who cannot join
- Moderate to severe action tremor in the dominant hand limiting the ability to perform the task.
- Upper limb peripheral neuropathy.
- Unable to read and understand English.
- 1. Unable to read and understand English.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Studies using functional MRI have shown reduced activation and connectivity in the right inferior parietal lobule, a region associated with agency.
The sense of agency consists of two components: the feeling of agency, which is an implicit, low-level sense of control over voluntary actions, and the judgment of agency, which is the conscious attribution of actions to oneself. While the feeling of agency is often measured using intentional binding tasks, judgment of agency is assessed using self-reported scales. While studies have explored intentional binding as a measure of implicit agency in FMD, few have systematically investigated judgment of agency. This study aims to fill this gap by introducing a novel approach that quantitatively evaluates judgment of agency in FMD patients using action-outcome latencies as an objective metric.
Read the detailed description
Objective: The objective of this study is to investigate the differences between patients with FMD and healthy controls in perceiving visual and auditory outcomes as consequences of their actions. This will be assessed by measuring their judgment of agency through action-outcome latencies.
- Conditions
- Functional Movement Disorder
- Keywords
- functional movement disorder, sense of agency, judgment of agency
- Medical subject headings
- Conversion Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cases | Functional Movement Disorder | |
| Controls | Healthy subjects |
What is being measured
The primary outcome is the main question the study is designed to answer.
SA Index
Latencies values corresponding to positive ("YES") responses will be extracted. SA (Sense of Agency) Index will be computed by multiplying the 90th percentile latencies by the number of positive responses below this latency threshold and then dividing the result by the total number of responses (positive, negative and unsure) occurring below the same threshold.
Measured: Day 1
Latencies
The 90th percentile of latency values among trials with positive ("YES") responses.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2025
- Study start31 Jan 2026 (estimated)
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Functional Movement DisorderStudies of the same condition, open and under way.
- More trials run by Western University, CanadaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western University, Canada
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aditya Murgai, Western University, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07302308
- Sponsor's protocol ID
- Action outcome latencies
- Status last verified
- Jan 2026
- First submitted
- 11 Dec 2025
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: At this time, IPD will not be shared due to confidentiality concerns.
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Action Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.
- ClinicalTrials.gov ID
- NCT07302308
- Acronym / sponsor ID
- Action outcome latencies
- Conditions
- Functional Movement Disorder
- Keywords
- functional movement disorder, sense of agency, judgment of agency
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Western University, CanadaUniversity, hospital or other
- Study start
- 31 Jan 2026 (estimated)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 24 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Functional movement disorders (FMD) are among the most common neurological conditions seen in clinical practice, yet they are poorly understood and often misdiagnosed. Impaired self-agency, the sense of controlling one's actions, is a key feature of FMD. Studies using functional MRI have shown reduced activation and connectivity in the right inferior parietal lobule, a region associated with agency.
The sense of agency consists of two components: the feeling of agency, which is an implicit, low-level sense of control over voluntary actions, and the judgment of agency, which is the conscious attribution of actions to oneself. While the feeling of agency is often measured using intentional binding tasks, judgment of agency is assessed using self-reported scales. While studies have explored intentional binding as a measure of implicit agency in FMD, few have systematically investigated judgment of agency. This study aims to fill this gap by introducing a novel approach that quantitatively evaluates judgment of agency in FMD patients using action-outcome latencies as an objective metric.
Detailed description
Objective: The objective of this study is to investigate the differences between patients with FMD and healthy controls in perceiving visual and auditory outcomes as consequences of their actions. This will be assessed by measuring their judgment of agency through action-outcome latencies.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases | – | –Functional Movement Disorder |
| Controls | – | –Healthy subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- movement disorder clinic
Key inclusion criteria (2 listed)
- Age >18 years.
- Able to read and understand English
Key exclusion criteria (4 listed)
- Moderate to severe action tremor in the dominant hand limiting the ability to perform the task.
- Upper limb peripheral neuropathy.
- Unable to read and understand English.
- 1. Unable to read and understand English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SA Index
Time frame: Day 1
Latencies values corresponding to positive ("YES") responses will be extracted. SA (Sense of Agency) Index will be computed by multiplying the 90th percentile latencies by the number of positive responses below this latency threshold and then dividing the result by the total number of responses (positive, negative and unsure) occurring below the same threshold.
Latencies
Time frame: Day 1
The 90th percentile of latency values among trials with positive ("YES") responses.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Individual participant dataSharing planned: No. At this time, IPD will not be shared due to confidentiality concerns.
Related trials for Functional Movement Disorder
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Parkinson Disease
RecruitingObservational study
Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
Parkinson Disease
Recruiting
Impact of rTMS on Abnormal Cortical fMRI in Patients With Dystonia
Dystonia Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Functional Movement Disorder, run by Western University, Canada at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aditya Murgai, MBBS MD DM (15196633121, aditya.murgai@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SA Index (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.